HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Karo Bio AB (STO:KARO)(publ) has received approval from national regulatory authorities to start its phase III patient study with eprotirome, enabling the study to start as planned with an Investigators meeting in September. "With these approvals, we have all key pieces in place to begin the large patient study in eprotirome’s phase III program. We, the clinicians and many patients are now looking forward to start this study", says Karo Bio’s acting CEO Per Bengtsson.
